Skip to main content
OTCMKTS:FTCY

Global Future City Competitors

$0.0000
0.00 (0.00 %)
(As of 01/24/2020)
Add
Compare
Today's Range
$0.00
$0.00
50-Day Range
$0.00
$0.05
52-Week Range
$0.05
$1.00
Volume16 shs
Average Volume4,221 shs
Market Capitalization$40.66
P/E RatioN/A
Dividend YieldN/A
Beta-0.61

Competitors

Global Future City (OTCMKTS:FTCY) Vs. ACUS, AFFY, ARYX, AHROQ, CBPI, and CDSG

Should you be buying FTCY stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Global Future City, including Acusphere (ACUS), Affymax (AFFY), ARYx Therapeutics (ARYX), AtheroNova (AHROQ), China Botanic Pharmaceutical (CBPI), and China Dongsheng International (CDSG).

Acusphere (OTCMKTS:ACUS) and Global Future City (OTCMKTS:FTCY) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability and analyst recommendations.

Volatility and Risk

Acusphere has a beta of -0.25, meaning that its share price is 125% less volatile than the S&P 500. Comparatively, Global Future City has a beta of -0.61, meaning that its share price is 161% less volatile than the S&P 500.

Profitability

This table compares Acusphere and Global Future City's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AcusphereN/AN/AN/A
Global Future CityN/AN/AN/A

Earnings and Valuation

This table compares Acusphere and Global Future City's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AcusphereN/AN/AN/AN/AN/A
Global Future CityN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for Acusphere and Global Future City, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acusphere0000N/A
Global Future City0000N/A

Summary

Acusphere beats Global Future City on 1 of the 1 factors compared between the two stocks.

Global Future City (OTCMKTS:FTCY) and Affymax (OTCMKTS:AFFY) are both finance companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.

Valuation and Earnings

This table compares Global Future City and Affymax's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Global Future CityN/AN/AN/AN/AN/A
AffymaxN/AN/AN/AN/AN/A

Volatility & Risk

Global Future City has a beta of -0.61, meaning that its share price is 161% less volatile than the S&P 500. Comparatively, Affymax has a beta of 2.77, meaning that its share price is 177% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Global Future City and Affymax, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Global Future City0000N/A
Affymax0000N/A

Profitability

This table compares Global Future City and Affymax's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Global Future CityN/AN/AN/A
AffymaxN/AN/AN/A

Summary

Affymax beats Global Future City on 1 of the 1 factors compared between the two stocks.

ARYx Therapeutics (OTCMKTS:ARYX) and Global Future City (OTCMKTS:FTCY) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability and valuation.

Profitability

This table compares ARYx Therapeutics and Global Future City's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ARYx TherapeuticsN/AN/AN/A
Global Future CityN/AN/AN/A

Volatility and Risk

ARYx Therapeutics has a beta of -0.53, meaning that its share price is 153% less volatile than the S&P 500. Comparatively, Global Future City has a beta of -0.61, meaning that its share price is 161% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for ARYx Therapeutics and Global Future City, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ARYx Therapeutics0000N/A
Global Future City0000N/A

Earnings & Valuation

This table compares ARYx Therapeutics and Global Future City's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ARYx TherapeuticsN/AN/AN/AN/AN/A
Global Future CityN/AN/AN/AN/AN/A

Summary

ARYx Therapeutics beats Global Future City on 1 of the 1 factors compared between the two stocks.

Global Future City (OTCMKTS:FTCY) and AtheroNova (OTCMKTS:AHROQ) are both finance companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, dividends, earnings and risk.

Profitability

This table compares Global Future City and AtheroNova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Global Future CityN/AN/AN/A
AtheroNovaN/AN/AN/A

Valuation and Earnings

This table compares Global Future City and AtheroNova's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Global Future CityN/AN/AN/AN/AN/A
AtheroNovaN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Global Future City and AtheroNova, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Global Future City0000N/A
AtheroNova0000N/A

Risk & Volatility

Global Future City has a beta of -0.61, suggesting that its share price is 161% less volatile than the S&P 500. Comparatively, AtheroNova has a beta of -8.71, suggesting that its share price is 971% less volatile than the S&P 500.

Summary

Global Future City beats AtheroNova on 1 of the 1 factors compared between the two stocks.

China Botanic Pharmaceutical (OTCMKTS:CBPI) and Global Future City (OTCMKTS:FTCY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Valuation & Earnings

This table compares China Botanic Pharmaceutical and Global Future City's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Botanic PharmaceuticalN/AN/AN/AN/AN/A
Global Future CityN/AN/AN/AN/AN/A

Profitability

This table compares China Botanic Pharmaceutical and Global Future City's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Botanic PharmaceuticalN/AN/AN/A
Global Future CityN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations for China Botanic Pharmaceutical and Global Future City, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Botanic Pharmaceutical0000N/A
Global Future City0000N/A

Risk and Volatility

China Botanic Pharmaceutical has a beta of 17.09, suggesting that its stock price is 1,609% more volatile than the S&P 500. Comparatively, Global Future City has a beta of -0.61, suggesting that its stock price is 161% less volatile than the S&P 500.

Summary

China Botanic Pharmaceutical beats Global Future City on 1 of the 1 factors compared between the two stocks.

Global Future City (OTCMKTS:FTCY) and China Dongsheng International (OTCMKTS:CDSG) are both finance companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Global Future City and China Dongsheng International, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Global Future City0000N/A
China Dongsheng International0000N/A

Profitability

This table compares Global Future City and China Dongsheng International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Global Future CityN/AN/AN/A
China Dongsheng InternationalN/AN/AN/A

Earnings & Valuation

This table compares Global Future City and China Dongsheng International's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Global Future CityN/AN/AN/AN/AN/A
China Dongsheng InternationalN/AN/AN/AN/AN/A

Volatility & Risk

Global Future City has a beta of -0.61, indicating that its share price is 161% less volatile than the S&P 500. Comparatively, China Dongsheng International has a beta of 13.38, indicating that its share price is 1,238% more volatile than the S&P 500.

Summary

China Dongsheng International beats Global Future City on 1 of the 1 factors compared between the two stocks.


Global Future City Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Acusphere logo
ACUS
Acusphere
0.0$0.05flat$0.00N/A0.00Gap Up
Affymax logo
AFFY
Affymax
0.6$0.09flat$0.00N/A0.00High Trading Volume
ARYX
ARYx Therapeutics
0.0$0.02flat$0.00N/A0.00High Trading Volume
Gap Up
AHROQ
AtheroNova
0.0$0.01flat$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.08flat$0.00N/A0.00Gap Up
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.06flat$0.00N/A0.00
China Health Industries logo
CHHE
China Health Industries
0.4$0.25flat$0.00$9.93 million4.20Upcoming Earnings
DDXSQ
Diadexus
0.0N/AN/A$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04flat$0.00N/A0.00
GLSI
Greenwich LifeSciences
2.0$32.95flat$0.00N/A0.00
HRBR
Harbor Diversified
0.0$1.70flat$0.00$263.61 million0.00Gap Down
IPAH
Interpharm
0.2$0.00flat$0.00N/A0.00
IRBS
IR Biosciences
0.0$0.00flat$0.00N/A0.00
MBVXQ
MabVax Therapeutics
0.0$0.02flat$0.00N/A0.00Gap Down
MYRX
Myrexis
0.5$0.05flat$0.00N/A0.00
NNBP
Nanobac Pharmaceuticals
0.0$0.00flat$0.00N/A0.00
PARD
Poniard Pharmaceuticals
0.5$0.09flat$0.00N/A0.00
SGTI
Shengtai Pharmaceutical
0.2$0.02flat$0.00N/A0.00
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00flat$0.00N/A0.00
SUWN
Sunwin Stevia International
0.5$0.05flat$0.00$26.09 million0.00Gap Up
Sycamore Entertainment Group logo
SEGI
Sycamore Entertainment Group
0.3$0.03flat$0.00N/A0.00Gap Up
SYNI
Synvista Therapeutics
0.0$0.00flat$0.00N/A0.00
TPIY
Tianyin Pharmaceutical
0.6$0.00flat$0.00N/A0.00High Trading Volume
Tibet Pharmaceuticals logo
TBET
Tibet Pharmaceuticals
0.0$0.01flat$0.00N/A0.00High Trading Volume
Gap Down
VOQP
VioQuest Pharmaceuticals
0.0$0.01flat$0.00N/A0.00
This page was last updated on 5/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.